ActoGeniX NV, Zwijnaarde, Belgium.
Ann N Y Acad Sci. 2009 Dec;1182:135-45. doi: 10.1111/j.1749-6632.2009.05067.x.
Interleukin-10 (IL-10) is central in immune downregulation, but so far its use in inflammatory diseases remains cumbersome. For treatment of inflammatory bowel disease, adequate amounts of IL-10 must reach the intestinal lining. Systemic injection of a pharmacologically active doses of recombinant human (rh) IL-10 results in very low mucosal levels of protein and severe toxicity and side effects. In animal models, topical and active delivery of IL-10 by ingestion of recombinant Lactococcus lactis (L. lactis) was shown to be a valuable alternative. Starting thereof we have developed a novel pharmaceutical platform. Our expertise and TopAct (topical and active) delivery technology allows use of recombinant L. lactis- ActoBiotics- in clinical practice. Here we discuss the development of recombinant L. lactis for intestinal delivery of rhIL-10 in humans.
白细胞介素-10（IL-10）在免疫下调中起核心作用，但迄今为止，其在炎症性疾病中的应用仍然很繁琐。为了治疗炎症性肠病，必须有足够量的 IL-10 到达肠黏膜。全身注射药理活性剂量的重组人（rh）IL-10 会导致黏膜蛋白水平极低，并伴有严重的毒性和副作用。在动物模型中，通过摄入重组乳球菌乳球菌（L. lactis）进行局部和主动传递 IL-10 被证明是一种有价值的替代方法。基于此，我们开发了一种新型药物平台。我们的专业知识和 TopAct（局部和主动）传递技术使我们能够在临床实践中使用重组乳球菌乳球菌 ActoBiotics-。在这里，我们讨论了用于在人类中肠道递送 rhIL-10 的重组乳球菌的开发。
